IPO registrations (S-1, F-1) · Registrants
Eloxx Pharmaceuticals, Inc.
- SEC CIK
- 1035354 · filings on EDGAR ↗
- Former names
- Sevion Therapeutics, Inc. (2014–2017); SENESCO TECHNOLOGIES INC (1999–2014); NAVA LEISURE USA INC (1997–1999)
- Registration
- Form S-1, first filed 2013-07-17, last 2026-09-11; 5 initial registrations, 8 amendments
- Outcome
- Final prospectus filed 2013-10-01; declared effective 2013-09-30; withdrawal requested 2016-10-31
- Industry (SIC)
- Biological Products, (No Diagnostic Substances) 2836
- Incorporated in
- DE
- Business address
- P.O. BOX 274, Arlington, MA 02476
- EIN
- 84-1368850
- Ticker
- ELOX (Nasdaq)
- EDGAR entity type
- operating
- Insiders and CEO pay
- Eloxx Pharmaceuticals, Inc. on the corporate pages
Offering terms
- Final price
- $5.00 per share (424B4 filed 2013-10-01)
- Shares sold
- 345,000
- Gross proceeds
- $1,725,000 before underwriting discounts and any over-allotment option
- Listing
- OTCQB under the symbol SNTI
Read from the cover pages of the filings listed under “Prospectus pages read” below; check the document for anything that matters.
On this site
- Form 5500 plan sponsor: ELOXX PHARMACEUTICALS, INC. EXACT (EIN (EXACT))
- Form D issuer: Sevion Therapeutics, Inc. EXACT (CIK (EXACT))
- SEC filer: Eloxx Pharmaceuticals, Inc. EXACT (CIK (EXACT))
- Person page: Miguel de los Rios Fuzzy (officer, director or 10% owner on the company's Forms 3, 4 and 5 (Officer))
Filings 25
| Filed | Form | What it is | Name as filed | EDGAR |
|---|---|---|---|---|
| 2013-07-17 | S-1 | S-1 (registration) | SENESCO TECHNOLOGIES INC | 0001144204-13-039968 ↗ |
| 2013-09-20 | S-1/A | S-1/A (amendment) | SENESCO TECHNOLOGIES INC | 0001144204-13-051820 ↗ |
| 2013-09-25 | S-1/A | S-1/A (amendment) | SENESCO TECHNOLOGIES INC | 0001144204-13-052398 ↗ |
| 2013-09-27 | S-1/A | S-1/A (amendment) | SENESCO TECHNOLOGIES INC | 0001144204-13-052767 ↗ |
| 2013-09-30 | EFFECT | EFFECT (declared effective) | SENESCO TECHNOLOGIES INC | 9999999995-13-002825 ↗ |
| 2013-10-01 | 424B4 | 424B4 (final prospectus) | SENESCO TECHNOLOGIES INC | 0001144204-13-053351 ↗ |
| 2013-10-17 | S-1 | S-1 (registration) | SENESCO TECHNOLOGIES INC | 0001144204-13-055661 ↗ |
| 2013-11-27 | S-1/A | S-1/A (amendment) | SENESCO TECHNOLOGIES INC | 0001144204-13-064464 ↗ |
| 2013-12-06 | S-1/A | S-1/A (amendment) | SENESCO TECHNOLOGIES INC | 0001144204-13-066138 ↗ |
| 2013-12-11 | S-1/A | S-1/A (amendment) | SENESCO TECHNOLOGIES INC | 0001144204-13-066729 ↗ |
| 2013-12-11 | EFFECT | EFFECT (declared effective) | SENESCO TECHNOLOGIES INC | 9999999995-13-003519 ↗ |
| 2013-12-12 | S-1MEF | S-1MEF (added securities) | SENESCO TECHNOLOGIES INC | 0001144204-13-066830 ↗ |
| 2013-12-12 | 424B4 | 424B4 (final prospectus) | SENESCO TECHNOLOGIES INC | 0001144204-13-066846 ↗ |
| 2015-10-09 | S-1 | S-1 (registration) | Sevion Therapeutics, Inc. | 0001144204-15-058943 ↗ |
| 2016-10-31 | RW | RW (withdrawal request) | Sevion Therapeutics, Inc. | 0001144204-16-130558 ↗ |
| 2018-04-20 | EFFECT | EFFECT (declared effective) | Eloxx Pharmaceuticals, Inc. | 9999999995-18-000879 ↗ |
| 2018-11-26 | EFFECT | EFFECT (declared effective) | Eloxx Pharmaceuticals, Inc. | 9999999995-18-002971 ↗ |
| 2021-08-30 | EFFECT | EFFECT (declared effective) | Eloxx Pharmaceuticals, Inc. | 9999999995-21-003359 ↗ |
| 2026-05-07 | S-1 | S-1 (registration) | Eloxx Pharmaceuticals, Inc. | 0001193125-26-212324 ↗ |
| 2026-06-01 | S-1/A | S-1/A (amendment) | Eloxx Pharmaceuticals, Inc. | 0001193125-26-251655 ↗ |
| 2026-06-04 | S-1/A | S-1/A (amendment) | Eloxx Pharmaceuticals, Inc. | 0001193125-26-257750 ↗ |
| 2026-06-08 | EFFECT | EFFECT (declared effective) | Eloxx Pharmaceuticals, Inc. | 9999999995-26-001918 ↗ |
| 2026-06-09 | 424B4 | 424B4 (final prospectus) | Eloxx Pharmaceuticals, Inc. | 0001193125-26-263914 ↗ |
| 2026-09-11 | S-1 | S-1 (registration) | Eloxx Pharmaceuticals, Inc. | 0001193125-26-389422 ↗ |
| 2026-09-18 | EFFECT | EFFECT (declared effective) | Eloxx Pharmaceuticals, Inc. | 9999999995-26-003014 ↗ |
Prospectus pages read 2
| Filed | Form | Read as | Range | Price | Shares | Proceeds | Listing | Underwriters | What was found | Document |
|---|---|---|---|---|---|---|---|---|---|---|
| 2013-09-27 | S-1/A | registration statement | 250,000 | - | OTCQB SNTI | 0 | primary document; shares headline | document ↗ | ||
| 2013-10-01 | 424B4 | final prospectus | $5.00 | 345,000 | $1,725,000 | OTCQB SNTI | 0 | primary document; price sentence, shares headline, proceeds computed | document ↗ |
Officers, directors and large holders Forms 3, 4 and 5
| Insider | Role | Title | Filings | Years | On this site |
|---|---|---|---|---|---|
| FORBES CHRISTOPHER | Director; Director,TenPercentOwner | 57 | 2006–2014 | ||
| BROOKS JOEL | Officer | CFO and Treasurer; CFO, Secretary and Treasurer; CFO, Secretary, Treasurer; Chief Financial Officer | 13 | 2006–2014 | |
| GALTON BRUCE C | Director,Officer; Other | President & CEO | 12 | 2006–2009 | |
| BRACA JOHN N | Director; Other | 29 | 2006–2017 | ||
| QUICK THOMAS C | Director | 24 | 2006–2014 | ||
| RECTOR DAVID | Director; Other | 28 | 2006–2017 | ||
| STALDER RUEDI | Director | 28 | 2006–2014 | ||
| Dondero Richard S | Officer | VP - Preclinical Research; VP Research; VP-Research; VP - Research and Development | 10 | 2006–2014 | |
| FEDYSZYN SASCHA P | Officer | VP - Corporate Dev. | 4 | 2006–2009 | |
| THOMPSON JOHN PHD | Director,Officer; Officer | Chief Scientific Officer; CSO; EVP and CSO; Scientific Founder | 8 | 2006–2014 | |
| Van Hulst Jack | Director; Director,Officer | President and CEO | 24 | 2007–2014 | |
| Waksal Harlan | Director | 28 | 2008–2015 | ||
| Isabelle Warren John | Director | 10 | 2009–2014 | ||
| Partlet Holdings Ltd | TenPercentOwner | 1 | 2009 | ||
| Browne Leslie J | Director,Officer; Officer | CEO; President; President and CEO | 11 | 2010–2014 | |
| Klaver Paul Edward | TenPercentOwner | 2 | 2012 | ||
| Frost Gamma Investments Trust | Director,TenPercentOwner; TenPercentOwner | 4 | 2014–2015 | ||
| FROST PHILLIP MD ET AL | Director; Director,TenPercentOwner; Other | 9 | 2014–2017 | ||
| GRAZIANO JAMES JOSEPH | Officer | Chief Technology Officer | 4 | 2014 | |
| RIOS MIGUEL DE LOS | Officer | VP - Research; VP- Research | 3 | 2014 | person page Fuzzy |
| Rubin Steven D | Director | 17 | 2014–2026 | ||
| SMIDER VAUGHN | Director,Officer; Director,Officer,TenPercentOwner | Chief Scientific Officer; See Remarks | 4 | 2014 | |
| MARTELL RON | Director,Officer | Chief Executive Officer | 3 | 2014 | |
| Opko Health, Inc. | TenPercentOwner | 4 | 2017 | ||
| WEAVER GREGORY L | Officer; Other | Chief Financial Officer; CHIEF FINANCIAL OFFICER | 8 | 2017–2020 | |
| Ward Robert | Director,Officer; Other | CHAIRMAN AND CEO; Chief Executive Officer; CHIEF EXECUTIVE OFFICER | 11 | 2017–2020 | |
| Avnur Zafrira | Director | 8 | 2017–2022 | ||
| Heft Robert | Director | 1 | 2017 | ||
| Huertas Pedro | Officer | Chief Medical Officer | 4 | 2017–2018 | |
| Kariv Tomer | Director | 11 | 2017–2023 | ||
| Kleijwegt Martijn | Director | 5 | 2017–2020 | ||
| Noiman Silvia | Director; Director,Officer | Chief Executive Officer | 5 | 2017–2020 | |
| Nussbaum Ran | Director | 11 | 2017–2022 | ||
| Pontifax (Cayman) III, L.P. | TenPercentOwner | 4 | 2017–2020 | ||
| Pontifax (Cayman) IV L.P. | TenPercentOwner | 8 | 2017–2021 | ||
| Pontifax (China) IV L.P. | TenPercentOwner | 8 | 2017–2021 | ||
| Pontifax (Israel) III, L.P. | TenPercentOwner | 4 | 2017–2020 | ||
| Pontifax (Israel) IV, L.P. | TenPercentOwner | 8 | 2017–2021 | ||
| Pontifax IV GP L.P. | TenPercentOwner | 8 | 2017–2021 | ||
| Pontifax Management 4 G.P. (2015) Ltd. | TenPercentOwner | 8 | 2017–2021 | ||
| Pontifax Management Fund III L.P. | TenPercentOwner | 4 | 2017–2020 | ||
| Pontifax Management III G.P. (2011) Ltd. | TenPercentOwner | 4 | 2017–2020 | ||
| Shabtai Gilad | TenPercentOwner | 4 | 2017–2018 | ||
| Veinrib Gadi | Director | 6 | 2017–2022 | ||
| Seehra Jasbir | Director | 6 | 2018–2022 | ||
| Belloff Neil S. | Officer | COO, GENERAL COUNSEL &CORP SEC; General Counsel and Secretary; GENERAL COUNSEL/CORPORATE SECR | 16 | 2018–2021 | |
| Snow David P. | Officer; Other | Chief Business Officer; CHIEF BUSINESS OFFICER | 7 | 2018–2020 | |
| Williams Gregory C. | Director,Officer; Director,OfficerOther; Officer | CHIEF EXECUTIVE OFFICER; Chief Operating Officer; CHIEF OPERATING OFFICER | 13 | 2018–2021 | |
| MacDonald Stephen G. | Officer | VP Finance & Acctg, Treasurer; VP FINANCE & ACCTG, TREASURER | 2 | 2021 | |
| Rakers Gary D. | Officer | Controller, PFO/PAO, Treasurer | 1 | 2021 | |
| Aggarwal Sumit | Director; Director,Officer; Director,Officer,TenPercentOwner | President and CEO; PRESIDENT AND CEO | 10 | 2021–2026 | |
| Geffken Daniel E. | Officer | Chief Financial Officer; CHIEF FINANCIAL OFFICER; INTERIM CFO | 3 | 2021 | |
| MODUR VIJAY | Officer | HEAD OF R&D | 5 | 2021–2023 | |
| Walts Alan Edmund | Director | 11 | 2021–2026 | ||
| PAREKH RAJESH B | Director | 5 | 2021–2022 | ||
| Androski Lindsay | Director | 6 | 2022–2025 | ||
| Coastlands Capital LP | TenPercentOwner | 2 | 2026 | ||
| Domicilium Real Estate Fund III LP | TenPercentOwner | 4 | 2026 | ||
| Kjellson Nina S | Director | 2 | 2026 | ||
| Webster Stephen W | Director | 2 | 2026 |
Everyone who filed an insider report for this company, from the SEC’s Insider Transactions Data Sets (2006 on). Person pages are matched by name and state only.
Private offerings before or after (Form D)
| First filed | Issuer | Industry | Offering | Sold | Investors | Filings |
|---|---|---|---|---|---|---|
| 2015-05-15 | Sevion Therapeutics, Inc. | Biotechnology | $10,000,000 | $3,023,746 | 14 | 1 |
Data: SEC EDGAR. The quarterly full index (every S-1, S-1/A, F-1 and F-1/A since 1993, with the pricing prospectus, notice of effectiveness and withdrawal request of each registrant) and the company submissions data (SIC, state of incorporation, address, EIN, tickers, former names). Company details are what EDGAR holds today, not at the time of the filing.
Also on this site Fuzzy
| Record | Name as filed | Where | Dataset | Matched by |
|---|---|---|---|---|
| Contractor | ELOXX PHARMACEUTICALS | MA | Nonprofit contractors (Form 990) | name and state |
| Form D issuer | Sevion Therapeutics, Inc. | CA | Form D private offerings | CIK (EXACT) |
| SEC filer | Eloxx Pharmaceuticals, Inc. | SEC filers (EDGAR) | CIK (EXACT) | |
| Form 5500 plan sponsor | ELOXX PHARMACEUTICALS, INC. | EIN (EXACT) | ||
| Person page | Miguel de los Rios | People (Form 990 officers, directors and employees) | officer, director or 10% owner on the company's Forms 3, 4 and 5 (Officer) |
Matched by an identifier (EIN, CIK, CRD), by name and state or city, or by street address; a shared name or address is not proof of the same person or organization. Every link says how it was made; how the cross-referencing works.
Others with the same interests
SIC industry Biological Products, (No Diagnostic Substances), MA first:
- TRANSCEND THERAPEUTICS INC MA
- PANACOS PHARMACEUTICALS, INC. MA
- CHARLES RIVER LABORATORIES INC MA
- AGENUS INC MA
- CURIS INC MA
- MOMENTA PHARMACEUTICALS INC MA
- ACCELERON PHARMA INC MA
- bluebird bio, Inc. MA
- Altus Pharmaceuticals Inc. MA
- BioVex Group, Inc. MA
In other datasets, the same topic (Health) in MA:
- Nonprofit: ABBIE M GRIFFIN HOSPITAL FUND (Nonprofits (IRS Form 990))
Interests: Biological Products, (No Diagnostic Substances) · Health